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Introduction {#sec005}
============

The prevalence of type 2 diabetes, a chronic disease which causes significant mortality, has increased considerably in world populations, representing a major public health issue \[[@pone.0134154.ref001]\]. Diabetes is associated with a clustering of cardiometabolic features including obesity, dyslipidaemia, hypertension, insulin resistance, chronic low-grade inflammation \[[@pone.0134154.ref002], [@pone.0134154.ref003]\], and may lead to severe cardiovascular complications \[[@pone.0134154.ref004]\].

Pre-diabetes, a condition defined by glycaemic profiles that are higher than normal but which do not meet thresholds for diabetes, is a strong risk factor for type 2 diabetes and related complications \[[@pone.0134154.ref005]\]. The American Diabetes Association (ADA) classifies type 2 diabetes as a fasting plasma glucose (FPG) level ≥7.0 mmol/l and pre-diabetes as impaired FPG levels between 5.6--6.9 mmol/l \[[@pone.0134154.ref002]\]. In 2009 the International Expert Committee recommended glycated haemoglobin A~1c~ (HbA~1c~) as an alternative marker \[[@pone.0134154.ref006]\], and in 2010 the ADA introduced HbA~1c~ cut-points of ≥6.5% (≥48 mmol/mol) for diabetes diagnosis and between 5.7--6.4% (39--46 mmol/mol) as a criterion to identify individuals at a high-risk state of developing diabetes \[[@pone.0134154.ref002]\]. Perceived benefits of the use of HbA~1c~ measurement, over FPG, include greater pre-analytical stability, lower biological variability and that the assay may be performed in non-fasting blood samples \[[@pone.0134154.ref007], [@pone.0134154.ref008]\]. However, use of HbA~1c~ as a screening tool has been controversial, with research showing discordance between HbA~1c~ and FPG \[[@pone.0134154.ref009]--[@pone.0134154.ref012]\], and several studies suggesting that factors such as age or ethnicity may influence diagnostic performance \[[@pone.0134154.ref013]--[@pone.0134154.ref015]\].

The aim of this study was to compare the metabolic profiles in subjects with pre-diabetes and type 2 diabetes, using ADA-recommended HbA~1c~ and FPG diagnostic thresholds, in a random sample of 2,047 middle-aged men and women. In particular, we examined a range of diabetes risk factors, metabolic syndrome (MetS) features, pro-inflammatory cytokines, acute-phase response proteins, coagulation factors and white blood cell (WBC) counts to determine which assay more accurately identifies individuals at increased cardiometabolic risk.

Materials and Methods {#sec006}
=====================

Study population {#sec007}
----------------

The Cork and Kerry Diabetes and Heart Disease Study (Phase II) was a single centre, cross-sectional study conducted between 2010 and 2011. A random sample was recruited from a large primary care centre in Mitchelstown, County Cork, Ireland. The Livinghealth Clinic serves a population of approximately 20,000 Caucasian-European subjects, with a mix of urban and rural residents. Stratified sampling was employed to recruit equal numbers of men and women from all registered attending patients in the 46--73 year age group. In total, 3,807 potential participants were selected from the practice list. Following the exclusion of duplicates, deaths, and subjects incapable of consenting or attending appointment, 3,051 were invited to participate in the study and of these, 2,047 (49.2% male) completed the questionnaire and physical examination components of the baseline assessment (response rate: 67.1%). The status of non-responders included individuals refusing to participate (59.4%) and those who did not reply (40.6%). Male subjects accounted for 53.7% of non-responders while 43.5% (vs. 42.8% of responders) were \>60 years of age. Details regarding the study design, sampling procedures and methods of data collection have been reported previously \[[@pone.0134154.ref016]\].

Ethics committee approval conforming to the Declaration of Helsinki was obtained from the Clinical Research Ethics Committee of University College Cork. A letter signed by the contact GP in the clinic was sent out to all selected participants with a reply slip indicating acceptance or refusal. All subjects gave signed informed consent, including permission to use their data for research purposes.

Clinical and laboratory procedures {#sec008}
----------------------------------

All study participants attended the clinic in the morning after an overnight fast and blood samples were taken on arrival. Data on age, gender, family diabetes history, physician-diagnosed type 2 diabetes and prescription (Rx) medication use were gathered through a self-completed General Health Questionnaire. Triglyceride and high density lipoprotein cholesterol (HDL-C) levels were measured by Cork University Hospital Biochemistry Laboratory on Olympus 5400 biochemistry analysers with Olympus reagents using standardised procedures and fresh samples (Olympus Diagnostica GmbH, Hamburg, Germany). Fasting glucose concentrations were determined using a glucose hexokinase assay (Olympus Life and Material Science Europa Ltd., Lismeehan, Co. Clare, Ireland) and HbA~1c~ levels were measured in the haematology laboratory on an automated high-pressure liquid chromatography instrument Tosoh G7 \[Tosoh HLC-723 (G7), Tosoh Europe N.V, Tessenderlo, Belgium\]. Serum insulin, c-reactive protein (CRP), tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), adiponectin, leptin, resistin and plasminogen activator inhibitor-1 (PAI-1) were assessed using a biochip array system (Evidence Investigator; Randox Laboratories, UK). Complement component 3 (C3) was measured by immunoturbidimetric assay (RX Daytona; Randox Laboratories). White blood cell counts were determined by flow cytometry technology as part of a full blood count.

Three independent measurements of systolic and diastolic blood pressure (BP) were obtained with the subject in a seated position using an Omron M7 digital sphygmomanometer (Omron Healthcare Co. Ltd., Japan). The mean of the second and third readings was considered to be a subject's BP. The weight and height of each participant were measured to the nearest 0.1 kg and 0.1 cm respectively. Portable electronic Tanita WB-100MA weighing scales (Tanita Corporation, IL, USA) were placed on a firm, flat surface and were calibrated weekly to ensure accuracy. Height was measured using a portable Seca Leicester height/length stadiometer (Seca, Birmingham, UK) and body mass index (BMI) was calculated as weight divided by the square of height. A BMI ≥30 kg/m^2^ was classified as obese. Waist circumference (WC) was measured between the lowest rib and iliac crest on bare skin. Subjects were instructed to breathe in, and then out, and to hold their breath while measurement was made to the nearest 0.1 cm using a Seca 200 measuring tape. Two independent measurements of WC were taken and the mean of the two was used in analysis. Central obesity was defined as a WC level ≥102 cm for males and ≥88 cm for females.

Classification of biochemical and blood pressure measurements {#sec009}
-------------------------------------------------------------

Lipid, lipoprotein and BP measurements were categorised according to National Cholesterol Education Program Adult Treatment Panel III (NCEP: ATP III) guidelines \[[@pone.0134154.ref017]\]. Abnormal metabolic risks were defined as high triglycerides ≥1.7 mmol/l and low HDL-C (\<1.03 mmol/l in males or \<1.29 mmol/l in females). Dyslipidaemia was determined according to both high triglyceride and low HDL-C levels. Elevated BP was classified as systolic BP ≥130 mmHg and/or diastolic BP ≥85 mmHg or Rx anti-hypertensive medication use. High serum insulin was defined as a level equal to or above the 75^th^ percentile in the study sample. Metabolic syndrome was determined according to a modified version of the NCEP: ATP III criterion, substituting serum insulin 75^th^ percentile for impaired FPG. Three or more MetS features (≥3 MetS) was characterised as any combination of the following: obesity defined by WC, high triglyceride levels, low HDL-C, elevated BP and high insulin concentrations. According to ADA guidelines, pre-diabetes was classified as elevated HbA~1c~ levels between 5.7--6.4% (39--46 mmol/mol) or impaired FPG levels between 5.6--6.9 mmol/l. Type 2 diabetes was defined as HbA~1c~ ≥6.5% (≥48 mmol/mol) or FPG ≥7.0 mmol/l \[[@pone.0134154.ref002]\]. As internationally recognised risk cut-points for the examined biomarkers have not been established, we classified inflammation and raised immune activation as a level above the study population median for each biomarker (C3, CRP, IL-6, TNF-α, leptin, resistin, PAI-1 and WBC) with the exception of adiponectin (below median level).

Statistical analysis {#sec010}
--------------------

Descriptive characteristics were examined according to diagnosis of pre-diabetes and type 2 diabetes. Categorical features are presented as percentages and continuous variables are displayed as a mean (plus or minus one standard deviation) or a median and interquartile range for skewed data. Binary logistic regression was used to explore diabetes-related risk factor and inflammatory biomarker relationships with pre-diabetes (compared to normoglycaemic subjects) and type 2 diabetes (compared to individuals without diabetes) defined using HbA~1c~ and FPG diagnostic cut-points. Models examining metabolic feature associations with pre-diabetes excluded patients with type 2 diabetes indicated by either HbA~1c~ or FPG, a physician diagnosis or Rx diabetes medication use. Risk feature relationships with pre-diabetes (either HbA~1c~ alone, FPG alone or dual categorisation by both HbA~1c~ and FPG) were further evaluated using multinomial logistic regression. Subjects classified as normoglycaemic by both assays were used as the reference category.

The ability of HbA~1c~ to discriminate pre-diabetes (defined by impaired FPG) and type 2 diabetes (defined by FPG levels ≥7.0 mmol/l) was assessed using receiver operating characteristic curve (ROC) analysis. The area under the curve (AUC) provides a scale from 0.5 to 1.0 (with 0.5 representing random chance and 1.0 indicating perfect discrimination) by which to compare the ability of a marker to detect a positive result \[[@pone.0134154.ref018]\]. The diagnostic properties of different HbA~1c~ thresholds were contrasted by determining sensitivity and false positive rates (FPR). Levels of agreement between diagnostic methods were ascertained using Cohen's kappa coefficient (K).

Primary data analysis was conducted using IBM SPSS Statistics Version 20 (IBM Corp., Armonk, NY, USA) for Windows. Confidence intervals for prevalence proportions were calculated using the VasserStats statistical website \[[@pone.0134154.ref019]\]. For all analyses, a P value (two-tailed) of less than 0.05 was considered to indicate statistical significance. Assay results for HbA~1c~ and FPG were available for 1,995 (97.5%) and 1,994 (97.4%) subjects. Participants missing either HbA~1c~ or FPG data were excluded from multinomial and ROC analyses. Low-level missing values were found within most independent variables. Sensitivity analysis indicated a similar percentage of missing data according to either HbA~1c~ or FPG pre-diabetes and diabetes classifications. Missing independent variable data were thus assumed to be ignorable and missing at random.

Results {#sec011}
=======

Descriptive characteristics {#sec012}
---------------------------

Characteristics of the study population according to pre-diabetes and type 2 diabetes classifications are presented in [Table 1](#pone.0134154.t001){ref-type="table"}. The prevalence of pre-diabetes was 49.1% (95% CI: 46.9%-51.3%) by elevated HbA~1c~ and 11.5% (95% CI: 10.2%-13.0%) by impaired FPG. Subjects categorised as pre-diabetic using HbA~1c~ had lower BMI and WC levels, lower triglyceride and insulin concentrations, higher HDL-C levels, were less hypertensive, and a greater proportion were female when compared to individuals with pre-diabetes defined by FPG.

10.1371/journal.pone.0134154.t001

###### Characteristics of the study population according to pre-diabetes and type 2 diabetes status.

![](pone.0134154.t001){#pone.0134154.t001g}

  Feature                                                  Full cohort         Pre-diabetes[^1^](#t001fn002){ref-type="table-fn"}   Type 2 diabetes[^2^](#t001fn003){ref-type="table-fn"}                        
  -------------------------------------------------------- ------------------- ---------------------------------------------------- ------------------------------------------------------- -------------------- --------------------
  Male                                                     1008 (49.2)         441 (45.0)                                           150 (65.2)                                              95 (65.1)            59 (69.4)
  Age                                                      59.0 (55.0--64.0)   60.0 (55.0--64.0)                                    61.0 (56.0--65.0)                                       60.0 (57.0--65.0)    61.0 (56.5--64.5)
  Age ≥60                                                  981 (47.9)          510 (52.0)                                           125 (54.3)                                              83 (56.8)            51 (60.0)
  Diagnosed diabetes                                       101 (4.9)           \-                                                   \-                                                      73 (50.0)            51 (60.0)
  On Rx for diabetes                                       78 (3.8)            \-                                                   \-                                                      60 (41.1)            41 (48.2)
  On Rx for hypertension                                   584 (28.5)          307 (31.3)                                           98 (42.6)                                               81 (55.5)            48 (56.5)
  On Rx for cholesterol                                    711 (34.7)          385 (39.3)                                           93 (40.4)                                               88 (60.3)            49 (57.6)
  BMI (kg/m2)                                              28.60 ± 4.7         28.80 ± 4.7                                          30.45 ± 5.2                                             32.17 ± 5.5          31.81 ± 5.5
  BMI ≥30                                                  668 (32.7)          345 (35.2)                                           109 (47.4)                                              85 (58.2)            49 (57.6)
  WC (cm)                                                  97.04 ± 13.2        97.08 ± 12.9                                         102.44 ± 12.8                                           107.91 ± 13.7        108.52 ± 13.9
  WC (HIGH)                                                1119 (54.8)         562 (57.4)                                           150 (65.2)                                              119 (81.5)           66 (77.6)
  Family diabetes history                                  390 (19.1)          176 (18.0)                                           46 (20.0)                                               62 (42.5)            41 (48.2)
  Triglycerides (mmol/l)                                   1.22 (0.9--1.7)     1.23 (0.9--1.7)                                      1.41 (1.0--2.0)                                         1.58 (1.2--2.3)      1.68 (1.2--2.3)
  Triglycerides ≥1.7                                       490 (24.6)          230 (23.8)                                           85 (37.9)                                               65 (45.5)            40 (48.8)
  HDL-C (mmol/l)                                           1.45 ± 0.4          1.45 ± 0.4                                           1.32 ± 0.3                                              1.17 ± 0.3           1.17 ± 0.4
  HDL-C (LOW)                                              353 (17.6)          165 (17.0)                                           59 (26.1)                                               66 (45.2)            35 (41.2)
  Dyslipidaemia                                            168 (8.4)           78 (8.0)                                             32 (14.0)                                               37 (25.3)            22 (25.9)
  Systolic BP (mmHg)                                       129.60 ± 16.8       130.10 ± 16.1                                        134.78 ± 15.5                                           134.19 ± 17.3        136.24 ± 17.4
  Diastolic BP (mmHg)                                      80.12 ± 9.7         80.24 ± 9.6                                          82.25 ± 9.1                                             79.50 ± 10.3         80.72 ± 10.5
  BP ≥130/85                                               1045 (51.3)         521 (53.4)                                           155 (67.7)                                              89 (61.4)            56 (66.7)
  HbA1c (%)                                                5.7 (5.5--6.0)      5.9 (5.7--6.0)                                       5.8 (5.6--6.1)                                          7.0 (6.7--8.1)       7.6 (6.8--9.0)
  HbA1c (mmol/mol)                                         39 (37--42)         41 (39--42)                                          40 (38--43)                                             53 (50--65)          60 (51--75)
  FPG (mmol/l)                                             4.90 (4.7--5.4)     5.00 (4.7--5.3)                                      5.80 (5.7--6.1)                                         6.90 (6.0--9.0)      8.50 (7.6--10.8)
  Insulin (μU/ml)                                          8.65 (5.3--14.1)    8.98 (4.6--11.8)                                     12.67 (7.4--19.5)                                       18.27 (10.6--31.9)   19.21 (12.1--30.9)
  Insulin 75th percentile                                  497 (25.0)          238 (24.6)                                           98 (43.2)                                               94 (65.7)            59 (70.2)
  ≥3 MetS features[^3^](#t001fn004){ref-type="table-fn"}   606 (29.6)          298 (30.4)                                           112 (48.7)                                              103 (70.5)           63 (74.1)
  C3 (mg/dl)                                               135.92 ± 24.7       138.85 ± 24.5                                        141.41 ± 25.8                                           148.13 ± 28.6        149.20 ± 24.9
  CRP (ng/ml)                                              1.35 (1.0--2.3)     1.43 (1.0--2.4)                                      1.38 (1.0--2.3)                                         1.79 (1.1--3.2)      1.91 (1.2--3.0)
  IL-6 (pg/ml)                                             1.81 (1.2--2.9)     1.91 (1.3--3.0)                                      2.02 (1.5--3.0)                                         2.92 (1.7--4.8)      2.83 (1.8--4.6)
  TNF-α (pg/ml)                                            5.97 (4.9--7.3)     6.02 (5.0--7.3)                                      5.94 (4.9--7.5)                                         6.99 (5.5--8.3)      7.09 (5.6--8.1)
  Adiponectin (ng/ml)                                      4.75 (2.9--7.5)     4.92 (3.1--7.5)                                      3.63 (2.4--5.6)                                         2.82 (1.7--4.6)      2.73 (1.9--4.7)
  Leptin (ng/ml)                                           1.95 (1.1--3.1)     2.09 (1.3--3.5)                                      2.06 (1.3--3.8)                                         2.28 (1.3--3.9)      2.09 (1.1--3.4)
  Resistin (ng/ml)                                         5.07 (3.9--6.7)     4.93 (3.8--6.6)                                      4.89 (3.7--6.7)                                         6.15 (4.6--7.3)      5.53 (4.5--7.3)
  PAI-1 (ng/ml)                                            27.38 ± 12.6        27.87 ± 12.0                                         29.56 ± 13.2                                            31.35 ± 15.9         30.03 ± 11.0
  WBC (109/l)                                              6.00 ± 1.9          6.12 ± 2.1                                           6.33 ± 1.72                                             7.39 ± 2.4           7.21 ± 1.9

Mean and ± standard deviation are shown for continuous variables. Age, triglycerides, HbA~1c~, FPG, insulin, CRP, IL-6, TNF-α, adiponectin, leptin and resistin are shown as a median (interquartile range). Numbers and % (in brackets) for categorical variables will vary in different analyses as some variables have missing values.

^1^Pre-diabetes: HbA~1c~ levels 5.7--6.4% (39--46 mmol/mol) or FPG levels 5.6--6.9 mmol/l.

^2^Type 2 diabetes: HbA~1c~ ≥6.5% (≥48 mmol/mol) or FPG ≥7.0 mmol/l.

^3^MetS features: WC (HIGH), triglycerides ≥1.7, HDL-C (LOW), BP ≥130/85 or Rx and insulin 75^th^ percentile.

Logistic regression {#sec013}
-------------------

In binary logistic regression analyses ([Table 2](#pone.0134154.t002){ref-type="table"}), associations between commonly assessed diabetes risk factors and pre-diabetes were stronger in subjects diagnosed by FPG. Odds ratios for pre-diabetes indicated by HbA~1c~ were non-significant for having a family diabetes history and elevated triglyceride levels, while there was a three-fold increased likelihood (OR: 3.0, 95% CI: 2.2--3.9) of having ≥3 MetS features in participants identified by FPG compared to an odds ratio of 1.6 (95% CI: 1.3--2.0) in pre-diabetes by HbA~1c~. In contrast, metabolic risk factor relationships with type 2 diabetes were generally comparable according to diagnosis by either assay, with odds ratios of having ≥3 MetS features being 6.1 (95% CI: 4.2--8.8) and 6.8 (95% CI: 4.1--11.2) for subjects diagnosed by HbA~1c~ and FPG respectively. Regardless of definition, patients with pre-diabetes and type 2 diabetes displayed a chronic pro-inflammatory profile as characterised by elevated C3, IL-6, WBC levels and reduced adiponectin concentrations.

10.1371/journal.pone.0134154.t002

###### Odds ratios (95% CI) of having risk factors according to diagnosis of pre-diabetes and type 2 diabetes by HbA~1c~ or FPG.

![](pone.0134154.t002){#pone.0134154.t002g}

  Feature                                                  Odds ratios (95% CI)[^1^](#t002fn001){ref-type="table-fn"}                                                                                      
  -------------------------------------------------------- ------------------------------------------------------------ --------- ---------------- --------- ----------------- --------- ----------------- ---------
  Male                                                     0.8 (0.6--0.9)                                               \<0.001   2.3 (1.7--3.0)   \<0.001   2.0 (1.4--2.9)    \<0.001   2.5 (1.5--3.9)    \<0.001
  Age ≥60                                                  1.6 (1.3--1.9)                                               \<0.001   1.4 (1.1--1.9)   0.011     1.5 (1.1--2.2)    0.018     1.7 (1.1--2.7)    0.017
  Family diabetes history                                  1.2 (0.9--1.5)                                               0.182     1.4 (1.0--2.1)   0.043     4.1 (2.9--5.9)    \<0.001   5.2 (3.3--8.1)    \<0.001
  BMI ≥30                                                  1.8 (1.4--2.2)                                               \<0.001   2.2 (1.7--3.0)   \<0.001   3.1 (2.2--4.3)    \<0.001   2.8 (1.8--4.4)    \<0.001
  WC (HIGH)                                                1.5 (1.2--1.9)                                               0.001     2.0 (1.4--3.1)   0.001     5.4 (2.5--11.8)   \<0.001   7.4 (2.3--23.5)   0.001
  Triglycerides ≥1.7                                       1.2 (0.9--1.5)                                               0.134     2.1 (1.5--2.8)   \<0.001   2.5 (1.8--3.6)    \<0.001   2.8 (1.8--4.4)    \<0.001
  HDL-C (LOW)                                              1.4 (1.1--1.8)                                               0.018     2.3 (1.7--3.3)   \<0.001   4.6 (3.2--6.6)    \<0.001   3.6 (2.3--5.7)    \<0.001
  Dyslipidaemia                                            1.6 (1.1--2.4)                                               0.019     2.6 (1.7--4.1)   \<0.001   4.3 (2.8--6.5)    \<0.001   4.1 (2.4--6.9)    \<0.001
  BP ≥130/85 or Rx                                         1.4 (1.2--1.7)                                               \<0.001   2.5 (1.8--3.5)   \<0.001   3.0 (1.9--4.8)    \<0.001   4.4 (2.2--8.6)    \<0.001
  Insulin 75^th^ percentile                                1.6 (1.3--2.0)                                               \<0.001   3.1 (2.3--4.2)   \<0.001   6.5 (4.5--9.4)    \<0.001   7.2 (4.4--11.7)   \<0.001
  ≥3 MetS features[^4^](#t002fn004){ref-type="table-fn"}   1.6 (1.3--2.0)                                               \<0.001   3.0 (2.2--3.9)   \<0.001   6.1 (4.2--8.8)    \<0.001   6.8 (4.1--11.2)   \<0.001
  C3[^5^](#t002fn005){ref-type="table-fn"}                 1.8 (1.5--2.2)                                               \<0.001   1.4 (1.0--1.8)   0.032     3.3 (2.2--4.9)    \<0.001   3.1 (1.9--5.0)    \<0.001
  CRP[^5^](#t002fn005){ref-type="table-fn"}                1.4 (1.1--1.7)                                               0.001     1.2 (0.9--1.5)   0.293     1.5 (1.1--2.2)    0.02      1.6 (1.0--2.6)    0.032
  IL-6[^5^](#t002fn005){ref-type="table-fn"}               1.6 (1.3--1.9)                                               \<0.001   1.5 (1.1--2.0)   0.005     2.8 (1.9--4.1)    \<0.001   2.8 (1.7--4.6)    \<0.001
  TNF-α[^5^](#t002fn005){ref-type="table-fn"}              1.2 (1.0--1.4)                                               0.078     1.0 (0.7--1.3)   0.738     2.3 (1.6--3.3)    \<0.001   2.7 (1.6--4.4)    \<0.001
  Adiponectin[^5^](#t002fn005){ref-type="table-fn"}        1.4 (1.1--1.7)                                               0.004     2.0 (1.4--2.7)   \<0.001   4.0 (2.5--6.2)    \<0.001   3.2 (1.8--5.6)    \<0.001
  Leptin[^5^](#t002fn005){ref-type="table-fn"}             1.5 (1.2--1.8)                                               \<0.001   1.4 (1.1--1.9)   0.014     1.5 (1.0--2.1)    0.026     1.2 (0.8--1.8)    0.48
  Resistin[^5^](#t002fn005){ref-type="table-fn"}           0.9 (0.8--1.1)                                               0.305     0.9 (0.7--1.2)   0.391     2.4 (1.7--3.5)    \<0.001   1.8 (1.1--2.8)    0.012
  PAI-1[^5^](#t002fn005){ref-type="table-fn"}              1.3 (1.1--1.6)                                               0.005     1.3 (1.0--1.7)   0.108     1.5 (1.0--2.1)    0.028     1.5 (1.0--2.4)    0.078
  WBC[^5^](#t002fn005){ref-type="table-fn"}                1.7 (1.4--2.1)                                               \<0.001   1.6 (1.2--2.1)   0.001     3.4 (2.3--5.0)    \<0.001   3.3 (2.0--5.5)    \<0.001

^1^Binary logistic regression. Gender adjusted for age (continuous), age ≥60 adjusted for gender, all other variables adjusted for age (continuous) and gender.

^2^Pre-diabetes: HbA~1c~ ≥5.7% (≥39 mmol/mol) or FPG ≥5.6 mmol/l, models exclude subjects with type 2 diabetes: HbA~1c~ ≥6.5% (≥48 mmol/mol) or FPG ≥7.0 mmol/l or physician diagnosis or Rx diabetes medication use.

^3^Models exclude 24 subjects that indicated a physician diagnosis or Rx diabetes medication use but who did not have positive HbA~1c~ or FPG test results.

^4^MetS features: WC (HIGH), triglycerides ≥1.7, HDL-C (LOW), BP ≥130/85 or Rx and insulin 75^th^ percentile.

^5^Threshold: above median level in the study population except adiponectin (below median level).

The results from multinomial regression models exploring risk factor relationships with pre-diabetes classified by HbA~1c~ alone, FPG alone, or by both HbA~1c~ and FPG together are displayed in [Table 3](#pone.0134154.t003){ref-type="table"}. Odds ratios for obesity, elevated BP, increased insulin concentrations and MetS were higher in participants classified by both assays, with four-fold increased odds (OR: 4.0, 95% CI: 2.8--5.8) of having ≥3 MetS features, compared to either HbA~1c~ (OR: 1.4, 95% CI: 1.2--1.8) or FPG (OR: 3.0, 95% CI: 1.7--5.1) alone. Stronger associations with markers of inflammation were also observed in subjects identified by both criteria.

10.1371/journal.pone.0134154.t003

###### Odds ratios (95% CI) of having risk factors according to diagnosis of pre-diabetes[^1^](#t003fn001){ref-type="table-fn"} by HbA~1c~ alone, FPG alone, or by both HbA~1c~ and FPG together.
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  Feature                                                  Odds ratios (95% CI)[^2^](#t003fn002){ref-type="table-fn"}                                                         
  -------------------------------------------------------- ------------------------------------------------------------ --------- ---------------- --------- ---------------- ---------
  Male                                                     0.8 (0.6--0.9)                                               0.006     3.3 (1.8--5.9)   \<0.001   1.6 (1.2--2.3)   0.005
  Age ≥60                                                  1.6 (1.3--1.9)                                               \<0.001   1.4 (0.8--2.3)   0.251     2.0 (1.4--2.8)   \<0.001
  Family diabetes history                                  1.1 (0.8--1.4)                                               0.474     1.2 (0.6--2.4)   0.651     1.7 (1.1--2.6)   0.013
  BMI ≥30                                                  1.6 (1.3--2.0)                                               \<0.001   1.7 (1.0--3.0)   0.051     3.4 (2.4--4.9)   \<0.001
  WC (HIGH)                                                1.4 (1.2--1.8)                                               \<0.001   2.0 (1.2--3.4)   0.011     2.6 (1.8--3.7)   \<0.001
  Triglycerides ≥1.7                                       1.2 (0.9--1.5)                                               0.267     2.5 (1.4--4.3)   0.001     2.3 (1.4--4.3)   \<0.001
  HDL-C (LOW)                                              1.3 (1.0--1.7)                                               0.095     2.5 (1.3--4.7)   0.004     2.8 (1.8--4.3)   \<0.001
  Dyslipidaemia                                            1.6 (1.0--2.5)                                               0.041     3.5 (1.6--7.8)   0.002     3.5 (2.0--6.2)   \<0.001
  BP ≥130/85 or Rx                                         1.3 (1.0--1.6)                                               0.012     2.2 (1.2--3.9)   0.009     3.3 (2.2--5.1)   \<0.001
  Insulin 75^th^ percentile                                1.5 (1.2--2.0)                                               0.002     3.4 (2.0--5.9)   \<0.001   4.1 (2.8--5.9)   \<0.001
  ≥3 MetS features[^3^](#t003fn003){ref-type="table-fn"}   1.4 (1.2--1.8)                                               0.003     3.0 (1.7--5.1)   \<0.001   4.0 (2.8--5.8)   \<0.001
  C3[^4^](#t003fn004){ref-type="table-fn"}                 1.8 (1.5--2.3)                                               \<0.001   1.4 (0.9--2.4)   0.17      2.2 (1.5--3.1)   \<0.001
  CRP[^4^](#t003fn004){ref-type="table-fn"}                1.4 (1.1--1.7)                                               0.002     1.1 (0.7--2.0)   0.640     1.5 (1.1--2.2)   0.017
  IL-6[^4^](#t003fn004){ref-type="table-fn"}               1.5 (1.2--1.9)                                               \<0.001   1.4 (0.8--2.4)   0.212     2.1 (1.5--3.0)   \<0.001
  TNF-α[^4^](#t003fn004){ref-type="table-fn"}              1.2 (1.0--1.5)                                               0.096     0.8 (0.5--1.4)   0.524     1.1 (0.8--1.6)   0.446
  Adiponectin[^4^](#t003fn004){ref-type="table-fn"}        1.3 (1.0--1.6)                                               0.043     1.3 (0.7--2.3)   0.373     2.6 (1.8--3.9)   \<0.001
  Leptin[^4^](#t003fn004){ref-type="table-fn"}             1.4 (1.2--1.8)                                               \<0.001   1.3 (0.8--2.2)   0.345     2.0 (1.4--2.9)   \<0.001
  Resistin[^4^](#t003fn004){ref-type="table-fn"}           1.0 (0.8--1.2)                                               0.626     1.3 (0.7--2.1)   0.389     0.8 (0.5--1.1)   0.139
  PAI-1[^4^](#t003fn004){ref-type="table-fn"}              1.3 (1.1--1.6)                                               0.008     1.4 (0.8--2.4)   0.2       1.6 (1.1--2.2)   0.014
  WBC[^4^](#t003fn004){ref-type="table-fn"}                1.6 (1.3--2.0)                                               \<0.001   1.3 (0.7--2.2)   0.371     2.6 (1.8--3.7)   \<0.001

^1^Pre-diabetes: HbA~1c~ ≥5.7% (≥39 mmol/mol) or FPG ≥5.6 mmol/l, models exclude subjects with type 2 diabetes: HbA~1c~ ≥6.5% (≥48 mmol/mol) or FPG ≥7.0 mmol/l or physician diagnosis or Rx diabetes medication use.

^2^Multinomial logistic regression, reference category: normoglycaemia by both HbA~1c~ and FPG. Gender adjusted for age (continuous), age ≥60 adjusted for gender, all other variables adjusted for age (continuous) and gender.

^3^MetS features: WC (HIGH), triglycerides ≥1.7, HDL-C (LOW), BP ≥130/85 or Rx and insulin 75^th^ percentile.

^4^Threshold: above median level in the study population except adiponectin (below median level).

ROC analysis {#sec014}
------------

Receiver operating characteristic curves for HbA~1c~ to detect pre-diabetes and type 2 diabetes are shown in Figs [1](#pone.0134154.g001){ref-type="fig"} and [2](#pone.0134154.g002){ref-type="fig"}. The ability of HbA~1c~ to discriminate pre-diabetes characterised by impaired FPG was low (AUC: 0.668, 95% CI: 0.627--0.710). The HbA~1c~ ≥5.7% (≥39 mmol/mol) pre-diabetes threshold demonstrated marginal sensitivity (72%) and a high FPR (52%). The level of agreement between both diagnostic methods was also poor (K: 0.084). Discriminatory capacity for type 2 diabetes defined by FPG ≥7.0 mmol/l was high (AUC: 0.941, 95% CI: 0.902--0.980). Sensitivity, FPR and kappa for the ADA-recommended HbA~1c~ ≥6.5% (≥48 mmol/mol) cut-off were 84%, 4% and 0.60 respectively.

![Receiver operating characteristic curve for HbA~1c~ to discriminate subjects with pre-diabetes.\
The figure shows an ROC curve for HbA~1c~ (continuous) to discriminate subjects with pre-diabetes (impaired FPG ≥5.6 mmol/l). The area under the curve value was AUC: 0.668, (95% CI: 0.627--0.710).](pone.0134154.g001){#pone.0134154.g001}

![Receiver operating characteristic curve for HbA~1c~ to discriminate subjects with type 2 diabetes.\
The figure shows an ROC curve for HbA~1c~ (continuous) to discriminate subjects with type 2 diabetes (FPG ≥7.0 mmol/l). The area under the curve value was AUC: 0.941, (95% CI: 0.902--0.980).](pone.0134154.g002){#pone.0134154.g002}

Discussion {#sec015}
==========

In this study of 2,047 middle-aged Caucasian-European men and women we show that subjects with HbA~1c~ levels 5.7--6.4% (39--46 mmol/mol) or FPG levels 5.6--6.9 mmol/l may exhibit different cardiometabolic profiles. Stronger relationships with diabetes-related risk features were found using impaired FPG compared to elevated HbA~1c~ to diagnose pre-diabetes. Conversely, the metabolic profiles of patients with type 2 diabetes, defined by either HbA~1c~ ≥6.5% (≥48 mmol/mol) or FPG ≥7.0 mmol/l concentrations, were broadly similar. In addition, it was noted that associations with risk factors and inflammatory markers were higher in pre-diabetic individuals classified by both assays. These results suggest that a combination of both criteria may be useful for detecting subjects at increased cardiometabolic risk.

Noticeably, within this population, a higher percentage of patients were identified as having pre-diabetes by HbA~1c~ (49.1% vs. 11.5% for FPG). A higher prevalence of pre-diabetes by HbA~1c~ in a United Kingdom cohort (N = 8,696) was also noted by Mostafa et al. \[[@pone.0134154.ref020]\], who reported a prevalence of 44.9% in participants diagnosed by HbA~1c~ compared to 16.2% in subjects detected by an oral glucose tolerance test (OGTT). Similar findings were determined using FPG as the glucose-based criterion. Our results are also consistent with those reported in a recent Chinese study (N = 2,318) and from research examining a Palestinian Arab population (N = 1,370). Du et al. \[[@pone.0134154.ref021]\] and Kharroubi et al. \[[@pone.0134154.ref022]\] found reasonable or moderate concordance between HbA~1c~ and FPG for type 2 diabetes, but a higher prevalence by HbA~1c~ and limited overlap for pre-diabetes using ADA-designated thresholds.

However, our results contrast with findings reported in the United States by the Insulin Resistance Atherosclerosis Study (N = 855), which found a higher prevalence of pre-diabetes by FPG (31.1% vs. 10.6% for HbA~1c~) \[[@pone.0134154.ref023]\]. Similarly, research utilising data from the National Health and Nutrition Examination Survey (1999--2006) found the prevalence of pre-diabetes in a sample of 7,029 adults to be 28.2% and 12.6% using FPG and HbA~1c~ respectively \[[@pone.0134154.ref024]\]. Possible reasons for observed prevalence disparities between HbA~1c~ and FPG may include age, gender or ethnic differences in examined populations \[[@pone.0134154.ref010], [@pone.0134154.ref014], [@pone.0134154.ref015]\]. In addition, as glucose continues to be metabolized in blood cells even after sampling, discrepancies may be due to biochemical analysis intervals within different studies \[[@pone.0134154.ref007], [@pone.0134154.ref022]\].

Longitudinal research has suggested that combined use of HbA~1c~ and FPG may be beneficial for identifying high-risk subjects. In two Asian studies, Inoue et al. \[[@pone.0134154.ref025]\] and Heianza et al. \[[@pone.0134154.ref026]\] demonstrated hazard ratios for type 2 diabetes to be greater for subjects classified by both assays when compared to those diagnosed by either HbA~1c~ or FPG separately. Findings from the Kansai Healthcare Study showed that joint use of both methods improved predictive ability \[[@pone.0134154.ref027]\]. In ROC analysis, AUCs for models including both HbA~1c~ and FPG were larger than those for HbA~1c~ (0.853 vs. 0.771; P\<0.001) or FPG (0.853 vs. 0.818; P\<0.001) alone. Recent research by Lipska et al. also revealed that addition of HbA~1c~ to a model with impaired FPG improved discrimination and calibration \[[@pone.0134154.ref028]\]. The results from the present study imply that the mechanism for this association is that individuals with diabetes-related phenotypes are more accurately identified using combined criteria.

Established risk factors for type 2 diabetes include obesity, raised triglyceride and low HDL-C levels, hypertension and insulin resistance \[[@pone.0134154.ref029]\]. In particular, subjects with a combination of these features have been shown to have a five-fold increased risk of developing diabetes \[[@pone.0134154.ref030]\]. Cardiovascular diseases, and in particular obesity-related type 2 diabetes, are also characterised by a low-grade but chronic inflammatory state \[[@pone.0134154.ref031], [@pone.0134154.ref032]\]. This may be reflected in an increased production of pro-inflammatory cytokines and also in higher levels of acute-phase response proteins, coagulation factors, macrophages and immune cells and lower levels of adiponectin, the anti-inflammatory adipokine \[[@pone.0134154.ref032], [@pone.0134154.ref033]\].

In our study it was noted that pre-diabetic individuals categorised by both assays demonstrated a stronger association with cardiometabolic feature clustering and displayed a more pro-inflammatory, pro-atherogenic, hypertensive and insulin resistant profile. Though few prospective studies have comprehensively identified features related to pre-diabetes development, it has been suggested that risk factors for pre-diabetes mirror those for type 2 diabetes \[[@pone.0134154.ref034]\]. Consequently, on the basis of the similar risk profiles noted in this study between pre-diabetes (defined using both HbA~1c~ and FPG) and type 2 diabetes (classified by either method), these findings also indicate that combined use of both assays may be clinically useful for detecting individuals at highest odds of developing diabetes.

Although HbA~1c~ has long been used as a marker for glycaemic control, its diagnostic performance for type 2 diabetes is still questioned \[[@pone.0134154.ref035]--[@pone.0134154.ref037]\]. Though a more expensive assay, when compared with FPG, HbA~1c~ has advantages including convenience, greater pre-analytical stability, lower biological variability and increasing international standardisation \[[@pone.0134154.ref007], [@pone.0134154.ref037]\]. Moreover, HbA~1c~ has been shown to correlate with cardiovascular disease and all-cause mortality \[[@pone.0134154.ref038]\]. However, as diabetes is clinically defined by elevated blood glucose, and not by glycation of proteins, there is concern that using HbA~1c~ to classify type 2 diabetes may lead to major changes in the pathophysiological paradigm that defines the condition \[[@pone.0134154.ref007]\]. Although a report from the United States inferred that diagnosis by HbA~1c~, rather than FPG, would not significantly alter type 2 diabetes prevalence, and that categorisation would remain unchanged in as many as 97.7% of subjects \[[@pone.0134154.ref039]\], evidence is still equivocal \[[@pone.0134154.ref040]\].

Notably, within our sample, a higher prevalence of diabetes was determined using HbA~1c~ (7.3%, 95% CI: 6.3%-8.6%) compared to FPG (4.3%, 95% CI: 3.5%-5.2%). However, a similar type 2 diabetes prevalence rate in middle-aged Irish adults, defined by HbA~1c~, was recently reported using data from the nationally representative 2007 Survey of Lifestyle, Attitudes and Nutrition (7.1%, 95% CI: 5.2%-9.0%) \[[@pone.0134154.ref040], [@pone.0134154.ref041]\]. It was also noted that diabetic subjects identified by HbA~1c~ or FPG within the present study displayed markedly similar cardiometabolic profiles. In addition, HbA~1c~ demonstrated high predictive ability for type 2 diabetes diagnosed by FPG ≥7.0 mmol/l levels. Conversely, HbA~1c~ showed poor discriminatory capacity for pre-diabetes defined by impaired FPG.

As HbA~1c~ reflects long-term glycaemic exposure, including postprandial glucose spikes, rather than the acute dysglycaemia indicated by FPG, it is rational to assume that each assay may identify different individuals. Our results suggest that HbA~1c~ may provide greater sensitivity for diagnosing type 2 diabetes within this sample. However, the limited overlap and substantially varied cardiometabolic profiles in subjects diagnosed with pre-diabetes, by either HbA~1c~ or FPG, imply that HbA~1c~ alone may lack specificity to accurately detect individuals at risk of diabetes development. It was also noted that metabolic risk profiles in pre-diabetic subjects, classified by impaired FPG levels only, were also considerably increased. This indicates that a percentage of high-risk individuals would be missed if HbA~1c~ was employed as a sole diagnostic criterion.

This study has several strengths, including a high participation rate (67%). As far as we are aware, ours is the first to compare pre-diabetes and type 2 diabetes prevalence, defined using both HbA~1c~ and FPG criteria, in a middle-aged Irish population. Additionally, few studies have compared a broad range of metabolic risk features and biomarkers with pre-diabetes and type 2 diabetes diagnosed by both assays. Our results are of potential clinical significance in terms of screening and the use of HbA~1c~ as a method for diagnosing diabetes and determining cardiometabolic risk. Accurate estimates of progression rates to type 2 diabetes are needed for efficient allocation of resources and to optimise public health prevention strategies \[[@pone.0134154.ref042]\]. Importantly, our findings indicate that caution should be taken with regard to how risk is defined as inexact methods may overestimate future diabetes burden \[[@pone.0134154.ref043], [@pone.0134154.ref044]\].

Notwithstanding these strengths, several limitations can be identified. These include single measurements of HbA~1c~ and FPG and that we did not have OGTT results as a comparison test. Although use of a third assay would have allowed a more thorough evaluation of HbA~1c~ and FPG, as discussed by Bonora et al. \[[@pone.0134154.ref007]\] comparisons between diagnostic methods for pre-diabetes and type 2 diabetes are ambiguous, as a true gold standard test is unavailable. Also, cross-sectional data precludes examination of temporal relationships. Consequently, though results from our research suggest associations between variables, they do not demonstrate an ability to predict type 2 diabetes or future cardiovascular events.

Equally of concern is that our data were derived from a single primary care based sample. Although results from the Cork and Kerry Diabetes and Heart Disease Study demonstrate prevalence rates for obesity and cardiovascular outcomes similar to those observed in other nationally representative Irish studies \[[@pone.0134154.ref040], [@pone.0134154.ref041], [@pone.0134154.ref045]\], the possibility that this sample is not representative of the source population must be acknowledged. However, previous research suggests that approximately 98% of Irish adults are registered with a GP and that, even in the absence of a universal patient registration system, it is possible to perform population-based epidemiological studies that are representative using these methods \[[@pone.0134154.ref046]\]. In addition, Ireland presents a generally ethnically homogeneous population \[[@pone.0134154.ref047]\]. Thus, the associations we observed between cardiometabolic features and HbA~1c~ and FPG may be comparable to other middle-aged Irish adults. As random sampling of subjects and the use of validated methods for data collection ensured internal sample validity, it is equally possible that the relationships described may be generalisable to a similar middle-aged, Caucasian-European population. Nevertheless, future studies utilising longitudinal data in different samples will be needed to confirm these findings. In particular, it will be necessary to determine whether risk stratification, using both assays, is clinically useful as a method for predicting type 2 diabetes.

Conclusions {#sec016}
===========

In summary, our results suggest that in middle-aged Caucasian-Europeans, when using ADA-recommended cut-points, HbA~1c~ alone is a poor indicator of diabetes risk, but is appropriate for type 2 diabetes diagnosis. Furthermore, combined use of HbA~1c~ and FPG identifies subjects at substantially increased cardiometabolic risk. Although the efficacy and cost-effectiveness of routine screening for diabetes in primary care has not been established \[[@pone.0134154.ref048]--[@pone.0134154.ref050]\], in light of the increasing prevalence of type 2 diabetes worldwide, there is a need to identify high-risk subjects. Dual screening, utilising both HbA~1c~ and FPG, may provide a more accurate method for predicting cardiometabolic events. Earlier diagnosis could enable earlier targeted interventions or therapies, thus attenuating development of type 2 diabetes and associated cardiovascular complications.
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